A ortic stenosis (AS) is a relatively common cause of cardiac debility and death, increasing in frequency and severity with age; indeed, AS of at least moderate severity may affect almost 8% of people Ն75 years of age. 1 The natural history of AS is dependent on the myocardial response to the abnormal left ventricular pressure load caused by the stenotic valve, involving cardiomyocyte hypertrophy, hyperproduction of extracellular matrix collagen by cardiac fibroblasts, and other alterations in myocardial biology. When these changes become critically severe, symptoms develop (angina pectoris, syncope, exertional dyspnea, and other manifestations of pulmonary vascular congestion) followed predictably by cardiac death at an annual rate of 25% unless aortic valve replacement surgery is performed.
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The basis of the lifesaving effect of aortic valve replacement is clear: the ventricular myocardium is unloaded, enabling myocardial remodeling toward normal, generally with recovery of normal myocardial performance. 2 A more satisfactory solution than surgery would be prevention of the stenotic process itself. To achieve this goal, the pathophysiology of stenosis development must be known, and effective pharmacological or other countermeasures must be developed and validated clinically.
The first step, elucidation of the pathobiology of AS, began more than a century ago (see, for example, Osler and Gibson 3 ) with the observation at necropsy that the heavily calcified aortic valves of patients with acquired AS of the "degenerative" or "senile calcific" form (now quantitatively the most common) manifest gross and histopathologic characteristics similar to those associated with atherosclerosis. The accretion of calcium in these lesions is pathophysiologically and prognostically important, and is commonly apparent with advancing age. Indeed, some calcification is present in the aortic valves of more than half the population Ն55 years of age. 1 Epidemiologic data now indicate that the risk factors promoting arterial atherosclerosis (including hypercholesterolemia, diabetes mellitus, hypertension, and smoking, as well as supernormal lipoprotein[a] concentration, expression of apolipoprotein E alleles, C-reactive protein concentration, etc.) also are associated with development and progression of AS. 4 -8 Therefore, it may be inferred that drugs known to modify these risk factors and to minimize atherosclerosis may also diminish progression of AS. The only rigorous test of this hypothesis is an appropriately designed randomized, controlled clinical trial. At least one such trial is now ongoing, assessing the combination of simvastatin and ezetamibe on AS progression; results are not yet available. Support for such clinical trials comes not only from histopathologic and epidemiological data but also from studies in experimental animals 9 and from several retrospective nonrandomized observational series suggesting that hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) can minimize progression of AS. 10 -12 The primary pharmacological effect presumed to underlie the inferred (not yet proven) impact of statins on AS is cholesterol lowering, supported not only by epidemiological data but also from evaluations of the cellular pathophysiology of AS. 9, 13, 14 Thus, it is presumed that calcification is induced by hypercholesterolemia.
Calcification is particularly relevant in the pathogenesis of AS because stiffening of the valve is the basis for hemodynamic deterioration, whereas valve calcification is directly related to the degree of stenosis. Prior studies suggest that the process of valve calcification is surprisingly similar to calcification in the bony skeleton: expression of mature lamellar bone and osteopontin have been demonstrated in human calcified stenotic aortic valves. 15, 16 In the study of Wu et al, in the current issue of this journal, the same group that made these observations now has provided exciting new insights into the cellular pathophysiology of calcification in AS and into its potential prevention. 17 Wu et al demonstrate that, in cultures of myofibroblasts isolated from porcine aortic valves, the effects of statins on bone formation can be dissociated from the effect on systemic cholesterol concentration, and that this action is mediated through inhibition of the cholesterol biosynthetic pathway. These observations provide a plausible basis for the earlier findings of Rajamannan et al, which demonstrated statin-mediated inhibition of cellular proliferation and bone matrix production in aortic valves of hypercholesterolemic rabbits. 9 The results of Wu et al provide important additional evidence favoring the specific beneficial effects of statins in preventing AS. In addition, these data suggest that the therapeutic target, prevention of calcification/bone formation, may be approachable by inhibiting the relevant pathway without reference to effects on cholesterol, thus widening the range of possible preventive strategies. To be sure, the studies of Wu et al were performed in a highly circumscribed experimental system. Relevance of this particular pharmacological effect of statins to prevention of aortic stenosis cannot be inferred directly from these findings. Nonetheless, this study adds importantly to the already strong mandate for clinical trials of statins to prevent progression of AS and, simultaneously, may stimulate novel approaches to prevention of neo-ossification in the aortic valve.
